Draft:Abigail Pulsipher

From Wikipedia, the free encyclopedia
  • Comment: Researcher has not been cited enough to be on Wikipedia, awards are not particularly prestigious. Noah 💬 02:36, 24 April 2024 (UTC)
Abigail Pulsipher
Born
Joint Base Andrews, Maryland, U.S.
NationalityAmerican
EducationUniversity of Virginia (BS, 2005)
University of North Carolina at Chapel Hill (PhD, 2011)
Scientific career
FieldsChronic Rhinosinusitis, Head and Neck Cancer, Glycobiology
InstitutionsUniversity of Utah, GlycoMira Therapeutics, Inc.
ThesisChemoselective Chemistry: Engineering Materials and Cell Surfaces to Control Biological Interactions (2012)
Websitehttps://uroclab.com

Abigail Pulsipher, PhD, is an American researcher focusing on the development of diagnostics and therapeutics for chronic rhinosinusitis (CRS). She currently holds a joint appointment at the University of Utah as an Assistant Professor in Otolaryngology - Head & Neck Surgery and as a Research Assistant Professor at Molecular Pharmaceutics.[1] Pulsipher also serves as a board member at GlycoMira Therapeutics. [1][2][3]  

Education[edit]

Pulsipher received a Bachelor of Science degree in Biochemistry from the University of Virginia. She then obtained her doctoral degree in Chemistry at the University of North Carolina at Chapel Hill, under the mentorship of Muhammad Yousaf. Following her graduation, she joined Linda Hsieh-Wilson lab at the California Institute of Technology as a post-doctoral fellow.[4]

Career and research[edit]

During her undergraduate years, Pulsipher participated in research on separating and characterizing phosphopeptides by microfluidics electrophoresis and mass spectrometry.[5] After graduating from the University of Virginia, she spent two years in the pharmaceutical industry working with Adenosine Therapeutics.

At the beginning of her doctoral studies, Pulsipher explored self-assembled monolayers (SAMs) modified with different chemical groups.[6] This work evolved into the engineering of cell surfaces. In one exemplary work, Pulsipher and colleagues used liposomes to deliver ketone or oxyamine groups to different cell populations. Through the bioorthogonal chemistry reaction between the two groups, they induced stable cell-cell contacts of human mesenchymal stem cells with fibroblasts to form a 3D tissue-like structure.[7] This research theme continued in her post-doctoral fellowship, where she further investigated cell surface glycan engineering, such as adding chondroitin sulfate glycosaminoglycans to neuronal cells for study of signaling pathway activation and growth of axons.[8]

Afterwards, Pulsipher dedicated seven years to GlycoMira Therapeutics, a biotechnology company in the area of polysaccharide-based immune system modulators. She held multiple leadership positions in several research departments, culminating in her role as a vice president of product development.[9] She actively participated in the development of GM-1111, a synthetic glycosaminoglycan-based drug with potential anti-inflammatory properties for sinonasal inflammations.[10] Currently, GM-1111 is under preclinical development.[11]

Pulsipher’s primary scientific contribution, which is also her most recent work, is basic and translational science research on chronic rhinosinusitis (CRS). This involves the gene expression profiles, such as the upregulated expression of cell adhesion molecules (CAMs), associated with the airway diseases[12][13]. In translational aspects, Pulsipher is investigating therapeutic and diagnostic options for CRS. Exemplary works include using PEGylated liposomes as a drug delivery agent[14] and a nasal-swab-based eosinophil peroxidase activity assay to detect eosinophilic CRS[15]. The significance of this work is highlighted by Pulsipher’s most recent grant received from the National Institute of Allergy and Infectious Diseases (NIAID).[16]  

Awards and honors[edit]

External links[edit]

 

References[edit]

  1. ^ a b "List of Core Members at the Utah Center for Nanomedicine". University of Utah College of Pharmacy. 10 November 2021. Retrieved March 24, 2024.
  2. ^ "Team Members". Utah Rhinology & Oncology Care (UROC) Innovations. Retrieved March 24, 2024.
  3. ^ "Team". GlycoMira. Retrieved April 23, 2024.
  4. ^ "List of Past and Current Members at the Hsieh-Wilson Lab". Hsieh-Wilson Lab. Retrieved March 24, 2024.
  5. ^ Yue, Guihua Eileen; Roper, Michael G.; Balchunas, Catherine; Pulsipher, Abigail; Coon, Joshua J.; Shabanowitz, Jeffery; Hunt, Donald F.; Landers, James P.; Ferrance, Jerome P. (March 2006). "Protein digestion and phosphopeptide enrichment on a glass microchip". Analytica Chimica Acta. 564 (1): 116–122. doi:10.1016/j.aca.2005.11.003. PMC 4631396. PMID 17723369.
  6. ^ Pulsipher, Abigail; Westcott, Nathan P.; Luo, Wei; Yousaf, Muhammad N. (10 June 2009). "Rapid in Situ Generation of Two Patterned Chemoselective Surface Chemistries from a Single Hydroxy-Terminated Surface Using Controlled Microfluidic Oxidation". Journal of the American Chemical Society. 131 (22): 7626–7632. doi:10.1021/ja809380e. PMID 19445524.
  7. ^ Dutta, Debjit; Pulsipher, Abigail; Luo, Wei; Yousaf, Muhammad N. (8 June 2011). "Synthetic Chemoselective Rewiring of Cell Surfaces: Generation of Three-Dimensional Tissue Structures". Journal of the American Chemical Society. 133 (22): 8704–8713. doi:10.1021/ja2022569.
  8. ^ Pulsipher, Abigail; Griffin, Matthew E.; Stone, Shannon E.; Brown, Joshua M.; Hsieh-Wilson, Linda C. (14 May 2014). "Directing Neuronal Signaling through Cell-Surface Glycan Engineering". Journal of the American Chemical Society. 136 (19): 6794–6797. doi:10.1021/ja5005174. PMC 4120997. PMID 24746277.
  9. ^ "Pulsipher's profile on LinkedIn". LinkedIn. Retrieved April 16, 2024.
  10. ^ Alt, Jeremiah A.; Lee, Won Yong; Davis, Brock M.; Savage, Justin R.; Kennedy, Thomas P.; Prestwich, Glenn D.; Pulsipher, Abigail (25 September 2018). "A synthetic glycosaminoglycan reduces sinonasal inflammation in a murine model of chronic rhinosinusitis". PLOS ONE. 13 (9): e0204709. doi:10.1371/journal.pone.0204709.
  11. ^ "A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis". NIH RePORTER. Retrieved March 26, 2024.
  12. ^ Gill, Amarbir S.; Pulsipher, Abigail; Sumsion, Jorgen S.; Howe, Heather; Alt, Jeremiah A. (May 2022). "Comorbid asthma may be associated with local inflammatory profile switching among patients with chronic rhinosinusitis without nasal polyposis". International Forum of Allergy & Rhinology. 12 (5): 784–787. doi:10.1002/alr.22917. PMID 34821066.
  13. ^ Blight, Brennan J; Gill, Amarbir S; Sumsion, Jorgen S; Pollard, Chelsea E; Ashby, Shaelene; Oakley, Gretchen M; Alt, Jeremiah A; Pulsipher, Abigail (May 2021). "Cell Adhesion Molecules are Upregulated and May Drive Inflammation in Chronic Rhinosinusitis with Nasal Polyposis". Journal of Asthma and Allergy. 14: 585–593. doi:10.2147/JAA.S307197. PMID 34079296.
  14. ^ Khurana, Nitish; Yathavan, Bhuvanesh; Jedrzkiewicz, Jolanta; Gill, Amarbir S.; Pulsipher, Abigail; Alt, Jeremiah A.; Ghandehari, Hamidreza (November 2021). "Vascular permeability in chronic rhinosinusitis enhances accumulation and retention of nanoscale pegylated liposomes". Nanomedicine: Nanotechnology, Biology and Medicine. 38: 102453. doi:10.1016/j.nano.2021.102453. PMID 34363985.
  15. ^ Smith, Kristine A.; Gill, Amarbir S.; Pollard, Chelsea E.; Sumsion, Jorgen S.; Saffari, Hedieh; Ashby, Shaelene; Witt, Benjamin L.; Shipman, Paige A.; Gabrielsen, David A.; Yim, Michael T.; Levy, Joshua M.; Oakley, Gretchen M.; Orlandi, Richard R.; Gleich, Gerald J.; Alt, Jeremiah A.; Pulsipher, Abigail (August 2023). "An eosinophil peroxidase activity assay accurately predicts eosinophilic chronic rhinosinusitis". Journal of Allergy and Clinical Immunology. 152 (2): 400–407. doi:10.1016/j.jaci.2023.04.012. PMID 37148919.
  16. ^ "Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis". NIH RePORTER. Retrieved March 24, 2024.
  17. ^ "Dr. Pulsipher Wins VPR SOM Seed Grant". University of Utah College of Pharmacy. 20 March 2023. Retrieved March 24, 2024.
  18. ^ "Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis". NIH RePORTER. Retrieved March 24, 2024.
  19. ^ "Dr. Pulsipher Named U of U CTSI K12 Scholar". University of Utah College of Pharmacy. 22 May 2023. Retrieved March 24, 2024.
  20. ^ "K12 Current Scholar". University of Utah Clinical and Translational Science Institute. 16 September 2020. Retrieved March 24, 2024.
  21. ^ "CTSA K12 Program at University of Utah: Early Career Faculty Development Program". NIH RePORTER. Retrieved March 24, 2024.
  22. ^ "Search Results for "abigail pulsipher"". NIH RePORTER. Retrieved March 24, 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Abigail_Pulsipher&oldid=1220489026"